Applied Filters
Valeant agrees to license Acanya in Actavis settlement
Canadian pharmaceutical company Valeant announced yesterday (May 12) that it had settled all litigation related to its acne treatment Acanya (clindamycin phosphate and benzoyl peroxide) with Actavis.
Acura settles Oxecta dispute with Ranbaxy
Acura Pharmaceuticals and Ranbaxy have agreed to settle their patent infringement litigation related to painkiller Aversion (oxycodone hydrochloride), once marketed by Pfizer under its registered trademark Oxecta.
FTC weighs in on “no-authorised-generic” antitrust case
The US Federal Trade Commission (FTC) has filed an amicus brief in an antitrust case that concerns a “no-authorised-generic” settlement between Teva and GlaxoSmithKline (GSK).
Cephalon launches another Treanda action
Cephalon has filed another lawsuit to protect its chronic lymphocytic leukaemia and non-Hodgkin’s lymphoma treatment Treanda (bendamustine hydrochloride), this time against Canadian pharmaceutical company Uman Pharma.
Actavis and Pfizer settle Celebrex litigation
Actavis has entered into an agreement with Pfizer to settle all outstanding patent litigation related to Pfizer’s arthritis drug Celebrex (celecoxib).
Federal Circuit rules against Roche in Tamiflu case
The US Court of Appeals for the Federal Circuit has thrown out a lower court ruling that found Natco Pharma infringed a patent covering Roche’s flu drug Tamiflu (oseltamivir phosphate).
Depomed settles with generics over Gralise dispute
Depomed, a California-based pharmaceutical company, has settled litigation with two of three companies that sought to launch generic versions of its Gralise (gabapentin) product before patents covering it expire.
Generics file Teva response in Copaxone battle
A group of generic drug manufacturers has asked the US Supreme Court to allow a ruling that grants them permission to market a version of Teva’s multiple sclerosis drug Copaxone (glatiramer acetate).
UK High Court strikes down Herceptin patents
The UK High Court has invalidated two patents covering Roche’s breast cancer drug Herceptin (trastuzumab) after a challenge by generic drug maker Hospira.
Purdue sues Teva to block OxyContin challenge
OxyContin (oxycodone hydrochloride) maker Purdue Pharma has filed suit against Teva to stop the generic drug maker trying to litigate claims to a patent for which it had filed a Paragraph III certification.
